Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Mavorixafor. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 known ✓ | P61073 | 20/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | DRD2 | P14416 | 1/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mavorixafor SCHEMBL29379072 | 1.00 | CXCR4 (1.00) | CXCR4CHRM2CYP2D6DRD2OPRM1 | |
| Mavorixafor SCHEMBL4716578 | 1.00 | CXCR4 (1.00) | CXCR4CHRM2CYP2D6DRD2OPRM1 | |
| Mavorixafor SCHEMBL1288182 | 1.00 | CXCR4 (1.00) | CXCR4CHRM2CYP2D6DRD2OPRM1 | |
| Mavorixafor SCHEMBL2511950 | 1.00 | CXCR4 (1.00) | CXCR4CHRM2CYP2D6DRD2OPRM1 | |
| Mavorixafor SCHEMBL29701264 | 1.00 | CXCR4 (1.00) | CXCR4CHRM2CYP2D6DRD2OPRM1 | |
| SCHEMBL2508418 | 0.99 | CXCR4 (1.00) | CXCR4CHRM2CYP2D6DRD2OPRM1 | |
| SCHEMBL2511014 | 0.99 | CXCR4 (1.00) | CXCR4CHRM2CYP2D6DRD2OPRM1 | |
| Mavorixafor SCHEMBL3798687 | 0.99 | CXCR4 (0.98) | CXCR4CHRM2CYP2D6DRD2OPRM1 | |
| SCHEMBL14131151 | 0.97 | CXCR4 (0.95) | CXCR4CHRM2CYP2D6DRD2OPRM1 | |
| SCHEMBL30096707 | 0.97 | CXCR4 (0.95) | CXCR4CHRM2CYP2D6DRD2OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4687960-A1 | METHODS OF HEMATOPOIETIC PRECURSOR CELLS MOBILIZATION | BioLineRx Ltd. (IL) | 2026-02-11 | — | — | EP | disclosed |
| WO-2025224720-A1 | METHODS OF SELECTING TREATMENT REGIMEN AGAINST SOLID TUMORS | BIOLINERX LTD. (IL) | 2025-10-30 | — | — | WO | disclosed |
| WO-2024201458-A1 | METHODS OF HEMATOPOIETIC PRECURSOR CELLS MOBILIZATION | BIOLINERX LTD. (IL) | 2024-10-03 | — | — | WO | disclosed |
| US-20230104343-A1 | CXCR4 INHIBITOR FOR THE TREATMENT OF ACUTE RESPIRATORY DISTRESS SYNDROME AND VIRAL INFECTIONS | BIOLINERX LTD. (IL) | 2023-04-06 | — | — | US | disclosed |
| EP-4117704-A1 | CXCR4 INHIBITOR FOR THE TREATMENT OF ACUTE RESPIRATORY DISTRESS SYNDROME AND VIRAL INFECTIONS | BioLineRx Ltd. (IL) | 2023-01-18 | — | — | EP | disclosed |
| US-20220409589-A1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS WITH ENHANCED EFFICACY | GENZYME CORP (US) | 2022-12-29 | — | — | US | disclosed |
| US-20220288155-A1 | CXCR4 INHIBITOR FOR THE TREATMENT OF ACUTE RESPIRATORY DISTRESS SYNDROME AND VIRAL INFECTIONS | BIOLINERX LTD. (IL) | 2022-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220409589-A1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS WITH ENHANCED EFFICACY | CCR5, CXCR4, CXCR3 | CXCR4 2/4885CHRM2 2757/4885CYP2D6 3057/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.